Key result
Intensive antihypertensive therapy significantly reduced morning home systolic blood pressure from 140 mmHg to 131 mmHg and decreased urinary protein excretion in diabetic patients with nephropathy.
Why the study?
Does intensive chronotherapeutic antihypertensive therapy (morning CCB/diuretic, evening ARB, bedtime alpha1-blocker) reduce morning home blood pressure and organ damage markers in patients with diabetic nephropathy?
Observational (n=57)
No
Does intensive chronotherapeutic antihypertensive therapy (morning CCB/diuretic, evening ARB, bedtime alpha1-blocker) reduce morning home blood pressure and organ damage markers in patients with diabetic nephropathy?
Absolute Event Rate: 131% vs 140%
p-value: p=0.032
Intensive chronotherapeutic antihypertensive regimens targeting morning blood pressure can significantly reduce morning hypertension and markers of renal and cardiovascular damage in patients with diabetic nephropathy.
May support intensive regimens targeting morning BP in diabetic nephropathy; hypothesis-generating pending RCTs on hard renal outcomes.
Blood pressure (BP) measured at home early in the morning (HBP) has been recognized as a useful predictor for organ damage and has been viewed as an important therapeutic target in patients with hypertension. The present study was aimed to determine whether this notion holds true in patients with progressive renal disease. The study enrolled patients with mild to moderate renal impairment. They were all directed to record self-measured HBP to evaluate the adequacy of BP control. In addition to the conventional antihypertensive therapy, intensive treatment to more efficiently reduce elevated morning HBP was applied, especially in patients with diabetic nephropathy. The results were as follows: 1) The status of BP control assessed using HBP and office/clinic BP (OBP) shows predominance of morning hypertension. The prevalence of patients with well-controlled systolic HBP was 38%, those with poorly-controlled HBP 30%, masked hypertension 20% and white coat hypertension 12%. 2) Early morning systolic HBP in diabetics was significantly higher than that in non-diabetics. However, when evaluated on systolic OBP, both groups were comparable.3)Logistic regression analysis showed that the predictive variables to explain morning hypertension (more than 130 mmHg and increased systolic HBP) were age, amount of daily urinary protein excretion and left ventricular mass index (LVMI).4)Following conventional therapy, intensive antihypertensive therapy consisting of calcium channel blockers (CCB) and/or diuretics given in the morning, and angiotensin receptor blockers (ARB) given in the evening, together with alpha1-blockers given at bedtime, efficaciously reduced elevated HBP in the morning. This result was associated with significant reduction in daily urinary protein excretion and in serum plasminogen-activator inhibitor (PAI-1) concentration. The present study indicates that, regardless of ongoing conventional antihypertensive therapy, the majority of patients with renal disease had morning hypertension, suggesting that these patients are at a higher risk for cardiovascular disease. For the purpose of improving morning hypertension, intensive treatments with combined CCB, ARB and alpha1-blockers could have substantial benefit on the morbidity and prognosis in patients with diabetic nephropathy.
No takes yet. Share an insight, caveat, or question.
Kuriyama et al. (2005) conducted an observational in Renal diseases (mild to moderate renal impairment) (n=57). Intensive antihypertensive therapy (CCB/diuretic, ARB, alpha1-blocker) vs. Baseline (conventional therapy) was evaluated on Morning home systolic blood pressure (mmHg) (p=0.032). Intensive antihypertensive therapy significantly reduced morning home systolic blood pressure from 140 mmHg to 131 mmHg and decreased urinary protein excretion in diabetic patients with nephropathy.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: